TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Truncal/Extremity Rash of Any Grade in Patients in the Spironolactone Arm
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of the Spironolactone Treatment to Prevent/Attenuate Rash From EGFR Inhibitors Defined as Absence of Any Grade 2 or Worse Rash
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Urine-positive Samples With Cocaine Positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Self-reported Past Week Cocaine Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection rate for moderate and severe dysplasia and CIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants who have perineal tears
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed ulcer bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fetal pulmonary acceleration time to ejection time ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Feasibility of the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Urinary Excretion of Alendronate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic Parameters AUC0-120 hr of Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Parameters Cmax of Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain visual analog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIGMA
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of CD3+/CD4+ Cells Per Cubic Millimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in FEV1 AUC0-3h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Carcinogenesis-related molecular markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: citalopram AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in OBS parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeline Follow-back (substance measure)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Targeting accuracy of HIFU ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment accuracy of HIFU ablation (radiologically determined)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of MRI guided transurethral HIFU ablation
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory Oxygenation index (ROX) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in UPDRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive Function composite
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Processing Speed composite
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Memory composite
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bioequivalence of Oseltamivir 75 mg capsules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emerging Adult Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parent-Emerging Adult Relationship Quality
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Emerging adult alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One year mortality
Endpoint domain: Mortality/survival
Primary endpoint: Six month mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Responders With a 50% or Greater Decrease on HAM-D17
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of general anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of HLA alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients developing brain metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nadir SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Novelty Preference Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Orienting Speed Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Sustained Focused Attention Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lab-TAB/Frustration Task Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Face-to-Face Still-Face Paradigm Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Culture Positivity at Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean blood dose after complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Elasticity of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep stage duration and transitions
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Pathological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: C. difficile pathogen count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: C. difficile spore count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: C. difficile Toxin Titers reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of HO on Humerus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of the diagnostic model in histological prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weight loss in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for the Pharmacokinetics (PK) of XZK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of genes predictive of clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of genes that change their prognostic profile with the addition of rituximab to CHOP chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body core temperature drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression or death of the patient
Endpoint domain: Mortality/survival
Primary endpoint: Change in cellular and viral micro ribonucleic acids (miRNAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: SAMANTA questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of specific SARS-CoV2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibiotic free days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: persistence rate after 24 weeks of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Lumbar Spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brown Adipose Tissue Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With a Grade 3 or High Toxicity/Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Amount of Prosocial Behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Subjects With Change From Normal to Abnormal in Fundus Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With a Change From Normal to Abnormal in Ocular Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Clinical Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: RMSSD Normal Breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of trans-thoracic ultrasound method and auscultation in left selective intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cmax of plasma salmeterol and fluticasone propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of plasma salmeterol and fluticasone propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Blood Oxygen Level Dependent (BOLD) Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real-World Progression Free Survival (rwPFS)
Endpoint domain: Mortality/survival
Primary endpoint: patients' preferences for survey technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients in sustained clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Physician Lesion Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of calcium supplement ingested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of PI3K inhibitor BKM120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (AE) of PI3K inhibitor BKM120
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving HBV DNA <1000 Copies/Milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Internalization of work motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of Resolvine Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Resolvine Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful biliary drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gross Motor Function Measure (GMFM-66)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mortality related to the procedure
Endpoint domain: Mortality/survival
Primary endpoint: Geometric Mean Titers (GMTs) Against Influenza B Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) Against Influenza A Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: measures of social function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: measures of repetitive behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first recurrence of symptomatic AF or atrial flutter/tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The GMFCS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental reported Bruxism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Tongue Thrust Rating Scale (TTRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drooling Severity and Frequency Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Water Swallowing Test (WST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in gene expression profile (FTO, BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ataxia, SARA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ataxia, ICARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ataxia, 9-hole pegboard test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysarthria, Radboud dysarthria assessment (RDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zygomatic Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of HepatoCellular Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amount of 24 hours morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change from baseline of FVC%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of AERAS-404
Endpoint domain: Adverse events/effects
Primary endpoint: State-Trait Anxiety Inventory (STAI; change between beginning and end of sessions)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Observable Focal-onset Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduced child abuse and neglect
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Head and Neck Radiotherapy Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline plasma 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vocal performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusing capacity of the lung for carbon monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest physician time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fe%0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in white matter values between normal and injured spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of GC1008
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pH of Saliva at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral Artery Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Femoral Artery Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Final diagnosis of acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking speed on the 10-meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength Performance Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blood Lipid Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent overnight in target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum measured plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antimicrobial Activity by Airway Surface Liquid (ASL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual Cancer Burden Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 1 Repetition maximum (1 RM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoring atopic dermatitis (SCORAD) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Wound Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in perceived stress scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Re-infection rate of intestinal parasitic infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: liver-transplantation free survival
Endpoint domain: Mortality/survival
Primary endpoint: Changes in plasma intact FGF23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity (neuropathy)
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity (liver function)
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence
Endpoint domain: Resource use
Primary endpoint: Visual analogue scale for pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wechsler Memory Scale, Third Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mini-Mental State Exam (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of LCRT to predict incidental lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under plasma concentration-time curve (AUC) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(0-last)) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Difference From Baseline IMRT Plan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of regenerated liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malaria incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feasibility and acceptability of study procedure
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Removal of Clostridium difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Associated organic soil load removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with abnormal OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart rate (HR) during exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen uptake (VO2) during exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak workload during exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported pain during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who develop anti-metreleptin/leptin antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who develop anti-metreleptin/leptin antibodies with neutralizing activity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Digestive tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patients discharged from hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital